Detection of minimal residual disease in acute myelogenous leukemia.

Abstract excerpt

Acute myelogenous leukemia (AML) is considered to be in complete remission when fewer than 5% of the cells in bone marrow are blasts. Nevertheless, approximately two thirds of patients relapse due to persisting leukemic blasts. The persistence of these cells, below the threshold of morphological detection, is termed minimal residual disease (MRD) and various methods are used for its detection. These methods...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Translocation, Genetic
• Share to Cytogenetics
• Share to In Situ Hybridization, Fluorescence